Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Smaller Deals
View:
Post by DeathXray33 on Sep 20, 2024 8:20am

Smaller Deals

Big Drugmakers Are Clinching Smaller Deals J&J, Merck and others are focusing on targets costing $5 billion or less, curtailing pricier acquisitions to help smooth regulators approval Aug. 12, 2024 5:30 am ET Merck has made four small acquisitions this year to diversify and deepen the companys drug pipeline. For years the worlds biggest drugmakers paid up for deals. Now they are writing much smaller checks. After shelling out tens of billions of dollars for single biotech companies, pharmaceutical giants such as AbbVie ABBV , AstraZeneca and Merck & Co. have shifted to smaller targets costing $5 billion or less. Many of the companies getting taken out are private. ------------------------------------------------ https://www.wsj.com/health/pharma/big-drugmakers-are-clinching-smaller-deals-0c039593?mod=pharma_more_article_pos12
Comment by TimboBaggins on Sep 20, 2024 10:03am
  5 Billion sounds ok to me 
Comment by Legit62 on Sep 20, 2024 10:19am
that sounds like a $20 a share buy out which im in favor of
Comment by Longholder99 on Sep 20, 2024 11:09am
BTD better run us up to $7 or $8 for a buyout to land in the $20 range.   Just thinking that a less than 20c SP to $20 is a steep jump....even if it takes a while.  Would have to be a frenzy of buying.  Our current 'in the weeds' and underfunded status belies any thoughts that we are an emergent stock market darling.  I wonder openly and am curious on any ...more  
Comment by chry200030 on Sep 20, 2024 12:49pm
The stock will move when it's ready. One can be pretty confident that TLT will not stay at .18 much longer, whether it's next week or in 6 months. This is a Super buying opportunity for those who are patient.
Comment by CAinPlap on Sep 20, 2024 2:49pm
It will move when management can show they can say we have rather than we hope or intend to.
Comment by Tarbaby on Sep 20, 2024 6:05pm
AGREED...but the main problem seems to be that most of their cash from the PPs goes to pay salaries and little is left for real lab work which is badly needed. Like live animal cancer implants to test different treatments. And toxicology tests even if not GLP. Just to state what dosage of Rutherrin is safe for injection..Which then extrapolates to human injections.. All this will be needed to gain ...more  
Comment by Tarbaby on Sep 20, 2024 6:30pm
AGREED...but the main problem seems to be that most of their cash from the PPs goes to pay salaries and little is left for real lab work which is badly needed. Like live animal cancer implants to test different treatments. And toxicology tests even if not GLP. Just to state what dosage of Rutherrin is safe for injection..Which then extrapolates to human injections.. All this will be needed to gain ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250